Transcranial magnetic stimulation as biomarker of excitability in drug development: A randomized, double-blind, placebo-controlled, cross-over study.

Ruijs, Titia Q; Heuberger, Jules A A C; de Goede, Annika A; Ziagkos, Dimitrios; Otto, Marije E; Doll, Robert J; van Putten, Michel J A M; Groeneveld, Geert Jan

Ruijs, Titia Q; Heuberger, Jules A A C; de Goede, Annika A; Ziagkos, Dimitrios; Otto, Marije E; Doll, Robert J; van Putten, Michel J A M; Groeneveld, Geert Jan.

Afiliação

Ruijs TQ; Centre for Human Drug Research, Leiden, The Netherlands.
Heuberger JAAC; Leiden University Medical Center (LUMC), Leiden, The Netherlands.
de Goede AA; Centre for Human Drug Research, Leiden, The Netherlands.
Ziagkos D; Centre for Human Drug Research, Leiden, The Netherlands.
Otto ME; University of Twente, Enschede, The Netherlands.
Doll RJ; Centre for Human Drug Research, Leiden, The Netherlands.
van Putten MJAM; Centre for Human Drug Research, Leiden, The Netherlands.
Groeneveld GJ; Centre for Human Drug Research, Leiden, The Netherlands.

Br J Clin Pharmacol ; 88(6): 2926-2937, 2022 06.

Article em En | MEDLINE | ID: mdl-35028950

Assuntos

Lorazepam; Estimulação Magnética Transcraniana; Biomarcadores; Estudos Cross-Over; Eletroencefalografia; Humanos; Levetiracetam/farmacologia; Lorazepam/farmacologia; Masculino; Preparações Farmacêuticas; Ácido Valproico/farmacologia

Palavras-chave

TMS-EEG; TMS-EMG; antiepileptic drugs; biomarkers; cortical excitability; levetiracetam; lorazepam; transcranial magnetic stimulation; valproic acid

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Estimulação Magnética Transcraniana / Lorazepam Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans / Male Idioma: En Revista: Br J Clin Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google